These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25690599)

  • 21. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sooner, the better: more evidence that early antiretroviral therapy lowers viral reservoirs in HIV-infected infants.
    Li JZ; Gandhi RT
    J Infect Dis; 2014 Nov; 210(10):1519-22. PubMed ID: 24850791
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
    Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
    AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.
    Cid-Silva P; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Pernas-Souto B; Llibre JM; Poveda E
    AIDS; 2018 Jan; 32(1):121-125. PubMed ID: 29112068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral therapy, CD4, viral load, and disease stage in HIV patients in Saudi Arabia: a 2001-2013 cross-sectional study.
    Memish ZA; Al-Tawfiq JA; Filemban SM; Qutb S; Fodail A; Ali B; Darweeish M
    J Infect Dev Ctries; 2015 Jul; 9(7):765-9. PubMed ID: 26230128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.
    White K; Kulkarni R; Miller MD
    J Antimicrob Chemother; 2015 Sep; 70(9):2632-8. PubMed ID: 26108607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?
    Vanham G; Buvé A; Florence E; Seguin-Devaux C; Sáez-Cirión A
    AIDS; 2014 Feb; 28(4):603-5. PubMed ID: 24401643
    [No Abstract]   [Full Text] [Related]  

  • 31. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjustment of antiretroviral regimen may lead to HBV reactivation even in patients with past HBV infection serological profile.
    Seang S; Thibault V; Valantin MA; Katlama C
    J Infect Chemother; 2013 Oct; 19(5):987-9. PubMed ID: 23380971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
    Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
    Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.
    Castro E; Zhao H; Cavassini M; Mullins JI; Pantaleo G; Bart PA
    AIDS; 2014 Jul; 28(12):1840-4. PubMed ID: 24911350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvements in virological control among women conceiving on combination antiretroviral therapy in Western Europe.
    Bailey H; Townsend CL; Cortina-Borja M; Thorne C;
    AIDS; 2013 Sep; 27(14):2312-5. PubMed ID: 23736151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral reduction: is it time to rethink the unthinkable?
    Colasanti J; Marconi VC; Taiwo B
    AIDS; 2014 Apr; 28(7):943-7. PubMed ID: 24401641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.